# South Korea Biologic Therapy Market > South Korea Biologic Therapy Market Research Report By Therapy Type (Monoclonal Antibodies, Vaccines, Cell Therapy, Gene Therapy), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By Route of Administration (Intravenous, Subcutaneous, Intramuscular) and By End User (Hospitals, Clinics, Home Healthcare) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.69% - **2024:** $ 7.8 Billion - **2025:** $ 8.32 Billion - **2035:** $ 15.9 Billion - **Key Players:** AbbVie (US), Amgen (US), Roche (CH), Johnson & Johnson (US), Novartis (CH), Pfizer (US), Bristol-Myers Squibb (US), Sanofi (FR), Gilead Sciences (US) **Report ID:** MRFR/Pharma/52743-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-biologic-therapy-market-54506 --- ## Market Summary ## **South Korea Biologic Therapy Market Overview** **As per MRFR analysis, the South Korea Biologic Therapy Market Size was estimated at 7.46 (USD Billion) in 2023.The South Korea Biologic Therapy Market Industry is expected to grow from 8.5(USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The South Korea Biologic Therapy Market CAGR (growth rate) is expected to be around 3.568% during the forecast period (2025 - 2035).** ## **Key South Korea Biologic Therapy Market Trends Highlighted** The South Korea Biologic Therapy Market is experiencing a notable shift towards the increasing adoption of personalized medicine, reflecting a global trend that emphasizes tailored treatments based on individual patient profiles. This trend is driven by advancements in genomics and biotechnology, which enable healthcare providers to design biologic therapies that target specific pathways in diseases, particularly in areas like oncology and autoimmune disorders. Additionally, the South Korean government supports the growth of the biologic therapy sector through initiatives that aim to enhance research, development, and production capabilities.  These efforts are complemented by increased funding for biotech startups and collaboration between academic institutions and industry players, fostering innovation within the field.Another important trend is the rising demand for biosimilars as a cost-effective alternative to original biologic products. South Korea has established a favorable regulatory environment that encourages the development of biosimilars, making it an attractive landscape for both local and international pharmaceutical companies. This expansion presents an opportunity for companies to explore partnerships that facilitate research and expedite the market entry of these therapies.  Moreover, there is a growing focus on the expansion of public awareness regarding biologic therapies, resulting in a more educated patient population that is actively seeking information on available treatment options.This increased awareness, fueled by both healthcare professionals and patient advocacy groups, offers opportunities for companies to educate and engage potential patients effectively. Overall, the South Korea Biologic Therapy Market reflects an environment rich with potential, driven by innovation, government support, and an informed consumer base. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South Korea Biologic Therapy Market Drivers** ### **Rising Incidence of Chronic Diseases** The South Korea Biologic Therapy Market Industry is being significantly driven by the increasing prevalence of chronic diseases, particularly autoimmune disorders and cancer. Recent data from the Ministry of Health and Welfare of South Korea indicates that the number of reported cancer cases has increased by 20% over the last decade, with approximately 230,000 new cases expected annually.  Additionally, organizations such as the Korean Cancer Association highlight the need for more advanced treatment options as traditional therapies often fall short for many patients.The rise in chronic disease prevalence necessitates innovative biological therapies, leading to an expanded market for such treatments in South Korea, providing opportunities for both local and international biotech companies to invest and further develop biologic therapies specific to these conditions. ### **Advances in Technology and Research** Technological advancements in biotechnology and Research and Development (R&D) are vital drivers for the South Korea Biologic Therapy Market Industry. The country has made significant investments in biopharmaceutical R&D, with the South Korean government increasing its budget for biotechnology research by 25% over the past five years.  The Korea Biotechnology Industry Organization (KOBIO) reports that over 300 biotech firms are actively engaged in developing biologic therapies, fostering an ecosystem of innovation.These advancements are likely to streamline the production processes, reduce costs, and enhance the efficacy of biologic therapies, thereby encouraging their adoption in clinical settings and supporting long-term market growth. ### **Supportive Regulatory Environment** South Korea has established a supportive regulatory framework to facilitate the approval and commercialization of biologic therapies. The Ministry of Food and Drug Safety (MFDS) has implemented expedited approval processes for innovative therapies, significantly reducing the typical time frame for bringing new biologics to market.  This approach not only encourages local companies but also attracts foreign investments, allowing international pharmaceutical giants to enter the South Korea Biologic Therapy Market Industry.Recent updates in the regulatory landscape reflect a commitment to industry growth, as evidenced by the fact that in 2022, over 40 new biological products were approved for use within the country, showcasing a proactive stance on promoting advanced medical treatments. ## **South Korea Biologic Therapy Market Segment Insights** ### **Biologic Therapy Market Therapy Type Insights** The South Korea Biologic Therapy Market showcases a diverse landscape within the Therapy Type segment, reflecting a significant adoption of innovative treatments geared towards addressing various health issues. Monoclonal antibodies have emerged as a key player, known for their precision in targeting specific cells, which plays a critical role in treating cancers and autoimmune diseases. The development of these therapeutics is supported by growing investments in Research and Development, coupled with a robust regulatory framework aimed at expediting the approval of new therapies.In recent years, the vaccines segment has gained unprecedented momentum bolstered by public health initiatives and the government's commitment to increasing vaccination rates, especially following the COVID-19 pandemic.  This has not only enhanced awareness but also fostered technological advancements leading to the development of more effective vaccines. Cell therapy is also gaining traction in South Korea, with its ability to regenerate damaged tissues and organs, making it a promising option for various degenerative diseases. The increasing prevalence of chronic illnesses and the aging population in South Korea drive the demand for such advanced treatments, posing significant opportunities for growth in the sector. Gene therapy, on the other hand, shows significant promise as a breakthrough technique to treating genetic illnesses by directly changing the disease-causing genes. The continuous research and trial efforts highlight the importance and potential of these medicines for improving patient outcomes. Collectively, these Therapy Type categories represent the dynamic evolution of the South Korean Biologic Therapy Market, reflecting technical advancements and the rising shift toward individualized medicine that meets the demands of the people. The market is underscored by a collaborative approach among stakeholders including healthcare providers, research institutions, and policy makers, driving innovation and ensuring that South Korea remains at the forefront of biologic therapy advancements. Source: Primary Research, Secondary Research, _Market Research Future_ Database and **Analyst Review** ### **Biologic Therapy Market Application Insights** The South Korea Biologic Therapy Market, particularly within the Application segment, showcases a comprehensive array of therapeutic areas, including Oncology, Autoimmune Diseases, Infectious Diseases, and Cardiovascular Diseases. Oncology has emerged as a significant contributor, driven by increasing cancer incidence rates, which necessitate advanced treatments. Autoimmune Diseases represent another vital area, attributed to rising awareness and prevalence, reflecting the region's healthcare shift towards personalized treatment.  On the other hand, the Infectious Diseases segment benefits from South Korea's robust public health infrastructure and advanced research capabilities, ensuring timely responses to emerging pathogens.Cardiovascular Diseases continue to pose a considerable health challenge, with biologic therapies becoming crucial in managing chronic conditions associated with this segment. Overall, the diversity of applications in the South Korea Biologic Therapy Market highlights the growing demand for specialized treatments, underpinned by substantial Research and Development investments and a supportive regulatory framework that fosters innovation. This dynamic environment ultimately enhances the prospects for market growth and drives the evolution of therapeutic strategies tailored to specific health conditions. ### **Biologic Therapy Market Route of Administration Insights** The South Korea Biologic Therapy Market is significantly influenced by the Route of Administration, which encompasses administration methods such as Intravenous, Subcutaneous, and Intramuscular deliveries. Intravenous administration is particularly important due to its ability to deliver larger volumes of biologic therapies rapidly into the bloodstream, ensuring immediate therapeutic effects. Conversely, Subcutaneous administration is notable for its convenience and patient compliance, allowing self-administration, which mitigates the challenges associated with hospital visits. Intramuscular administration serves as an effective method for therapies that require slower absorption rates, thereby maintaining a prolonged therapeutic effect. In South Korea, the increasing prevalence of chronic diseases and advancements in biologic therapies are driving the demand for these various routes of administration. As healthcare systems continue to evolve, the preference for less invasive, patient-friendly routes enhances the growth potential of biologics, shaping the South Korea Biologic Therapy Market dynamics significantly. The focus on optimizing these routes not only improves treatment outcomes but also supports broader trends toward personalized medicine and enhanced patient care in the region. ### **Biologic Therapy Market End User Insights** The End User segment of the South Korea Biologic Therapy Market plays a crucial role in determining the overall landscape and growth potential of the industry. Hospitals are typically at the forefront of biologic therapies, offering advanced treatment options for patients with chronic and complex conditions, thus driving a significant demand for these therapies. Clinics also contribute to the market by providing outpatient care and specialized treatments, enhancing access to biologic therapies and increasing patient volume.  Additionally, Home Healthcare is gaining traction, as it allows patients to receive therapies in the comfort of their own homes, improving adherence to treatment regimens while reducing hospital readmissions.This tailored approach to patient care not only enhances the quality of life but also accommodates the aging population in South Korea, who increasingly prefer home-based solutions. Furthermore, the increasing incidence of chronic diseases and the growing emphasis on personalized medicine are further propelling the demand across all End User categories. Overall, the South Korea Biologic Therapy Market segmentation reflects a diverse landscape with each End User demonstrating significant importance in catering to the evolving healthcare needs of the population. ## **South Korea Biologic Therapy Market Key Players and Competitive Insights** The South Korea Biologic Therapy Market is witnessing significant growth and evolution, characterized by rising innovations, strategic collaborations, and an increasing focus on patient-centric treatments. In this vibrant landscape, various players are competing to carve out niche markets and establish their positions as key contributors to health care advancements. The current market is marked by a plethora of biologics that cater to a range of therapeutic areas, including autoimmune diseases, oncology, and infectious diseases. With stringent regulatory frameworks and an emphasis on product efficacy and safety, companies have been striving to ensure compliance while enhancing their product portfolios.  The market dynamics are being influenced by factors such as growing incidences of chronic diseases, an aging population, and increased healthcare spending, drawing attentiveness from both global and local firms aiming to leverage South Korea's robust biotechnology ecosystem.In the context of the South Korean Biologic Therapy Market, EirGenix has established a noteworthy presence, focusing on the development and manufacturing of high-quality biological products. The company's pivotal strength lies in its robust manufacturing capabilities, which allow for flexibility and scalability, ensuring a swift response to market demands.  EirGenix excels in the development of monoclonal antibodies and biosimilars, positioning itself strategically to address the growing demand for cost-effective therapeutic options. Furthermore, EirGenix's commitment to research and development emphasizes its innovative approach in the biologics field, allowing it to stay competitive and cater to evolving patient needs. The firm's effective operational strategies and partnerships with local healthcare providers have also contributed to its growing reputation in the South Korean market, enabling it to enhance its product offerings effectively.Samyang Biopharmaceuticals is a prominent player in the South Korean Biologic Therapy Market, recognized for its comprehensive portfolio of therapeutic solutions. The company specializes in biopharmaceuticals, particularly in the areas of oncology and autoimmune diseases.  Leveraging advanced technologies, Samyang's key products include innovative biologic drugs that target specific disease pathways, demonstrating its strength in precision medicine. The company is well-positioned in the market due to its strong pipeline of therapies, which are developed with a keen focus on unmet medical needs. Recent mergers and acquisitions further exemplify Samyang's strategy to bolster its market presence and expand its R&D capabilities. These strategic moves not only enhance its product offerings but also reinforce its commitment to leading advancements in biologics. With an emphasis on collaboration with academic institutions and research organizations, Samyang Biopharmaceuticals continues to thrive in South Korea's competitive landscape, underscoring its critical role in shaping the future of biologic therapies. ### **Key Companies in the South Korea Biologic Therapy Market Include:** - [EirGenix](https://www.eirgenix.com/products) - Samyang Biopharmaceuticals - SK Biopharmaceuticals - Hugel - Celltrion - LG Chem - Daewoong Pharmaceutical - Hanmi Pharmaceutical - Genexine - Green Cross Corporation - MedAccess - KB Pharmaceuticals - Samsung Biologics - Chugai Pharmaceutical ## **South Korea Biologic Therapy Market Industry Developments** Recent developments in the South Korea Biologic Therapy Market have shown significant advancements and strategic movements among key players. In October 2023, LG Chem announced positive results from its clinical trials for a new biologic therapy, potentially enhancing its position in the market. EirGenix has also been expanding its portfolio, with new partnerships aimed at increasing accessibility to its products.  Meanwhile, SK Biopharmaceuticals reported a 15% growth in market valuation due to the successful launch of a novel therapy aimed at neurological disorders. Mergers and acquisitions have marked the recent landscape; for instance, in September 2023, Samsung Biologics completed the acquisition of a smaller biotech firm, enhancing its Production capabilities. In August 2023, Hanmi Pharmaceutical announced a partnership with Genexine for the joint development of a groundbreaking drug targeting autoimmune diseases.  The South Korean Biologic Therapy Market has been bolstered by these strategic moves along with governmental support for biopharmaceutical innovations, which includes incentives for Research and Development initiatives and funding opportunities for start-ups in this sector. These elements collectively indicate a dynamic and rapidly evolving market landscape in South Korea. ## **South Korea Biologic Therapy Market Segmentation Insights** ### **Biologic Therapy Market Therapy Type Outlook** - Monoclonal Antibodies - Vaccines - Cell Therapy - [Gene Therapy](../../../reports/gene-therapy-market-8399) ### **Biologic Therapy Market Application Outlook** - Oncology - Autoimmune Diseases - Infectious Diseases - Cardiovascular Diseases ### **Biologic Therapy Market Route of Administration Outlook** - Intravenous - Subcutaneous - Intramuscular ### **Biologic Therapy Market End User Outlook** - Hospitals - Clinics - Home Healthcare ## Market Drivers ### Growing Prevalence of Chronic Diseases The increasing incidence of chronic diseases in South Korea is a pivotal driver for the biologic therapy market. Conditions such as rheumatoid arthritis, psoriasis, and various cancers are becoming more prevalent, necessitating advanced treatment options. According to recent health statistics, chronic diseases account for approximately 80% of healthcare expenditures in the country. This trend underscores the urgent need for effective biologic therapies, which are often more targeted and have fewer side effects compared to traditional treatments. As the population ages and lifestyle-related diseases rise, the biologic therapy market is likely to expand significantly, with a projected growth rate of around 10% annually over the next five years. This growth reflects the increasing reliance on biologics to manage complex health conditions, thereby driving innovation and investment in the sector. ### Increasing Patient Awareness and Education Patient awareness and education regarding biologic therapies are on the rise in South Korea, significantly impacting the biologic therapy market. As patients become more informed about their treatment options, there is a growing demand for advanced therapies that offer better efficacy and safety profiles. Educational campaigns by healthcare providers and patient advocacy groups have played a crucial role in disseminating information about the benefits of biologics. This heightened awareness is reflected in patient inquiries and discussions with healthcare professionals, leading to an increase in prescriptions for biologic therapies. The trend suggests that as patients become more proactive in managing their health, the biologic therapy market may see a corresponding increase in demand, potentially driving market growth by an estimated 8% annually. ### Rising Healthcare Expenditure and Investment The upward trend in healthcare expenditure in South Korea is a significant driver for the biologic therapy market. With healthcare spending projected to reach 12% of GDP by 2026, there is a growing emphasis on innovative treatment options that can improve patient outcomes. Biologic therapies, known for their efficacy in treating complex diseases, are increasingly being integrated into treatment protocols. The government and private sectors are investing heavily in healthcare infrastructure, with an estimated $2 billion allocated for the development of advanced medical technologies. This investment is likely to enhance the accessibility and affordability of biologic therapies, thereby expanding the market. As healthcare providers seek to adopt cutting-edge treatments, the biologic therapy market is expected to experience robust growth in the coming years. ### Advancements in Biologic Research and Development Innovations in research and development are propelling the biologic therapy market forward in South Korea. The country is home to numerous biotech firms and research institutions that are at the forefront of developing novel biologic therapies. Recent investments in biotechnology have led to breakthroughs in monoclonal antibodies and gene therapies, which are transforming treatment paradigms. The South Korean government has allocated substantial funding, estimated at over $500 million annually, to support biotech research initiatives. This commitment fosters a conducive environment for clinical trials and product development, enhancing the competitiveness of the biologic therapy market. As new therapies emerge, they are expected to address unmet medical needs, further stimulating market growth and attracting both domestic and international investments. ### Regulatory Support and Streamlined Approval Processes Regulatory frameworks in South Korea are increasingly supportive of the biologic therapy market, facilitating faster approval processes for new treatments. The Ministry of Food and Drug Safety (MFDS) has implemented measures to expedite the review of biologics, which is crucial for bringing innovative therapies to market. Recent reforms have reduced the average approval time for biologics to approximately 12 months, compared to 18 months previously. This efficiency not only benefits patients by providing quicker access to new therapies but also encourages pharmaceutical companies to invest in the development of biologics. The favorable regulatory environment is likely to enhance the attractiveness of the biologic therapy market, potentially leading to a surge in new product launches and increased competition among manufacturers. ## Future Outlook The [Biologic Therapy Market](https://www.marketresearchfuture.com/reports/biologic-therapy-market-840) is projected to grow at a 6.69% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increasing chronic disease prevalence, and regulatory support. **New opportunities:** - Development of biosimilars to enhance market access and affordability. - Investment in telehealth platforms for remote biologic therapy management. - Partnerships with healthcare providers for integrated care solutions. By 2035, the biologic therapy market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Monoclonal Antibodies (Largest) vs. Cell Therapy (Fastest-Growing) In the South Korea biologic therapy market, Monoclonal Antibodies hold the largest market share, outperforming other segment values such as Vaccines, Cell Therapy, and Gene Therapy. This dominance is attributed to their established use and effectiveness in treating various diseases, alongside supportive government policies that favor their development. Conversely, Cell Therapy is emerging as a significant player, gaining traction due to advancements in technology and an increasing number of clinical trials, which bolster confidence among stakeholders. Growth trends in this market highlight a shift towards innovative therapies, with Cell Therapy paving the way as the fastest-growing segment. The rising prevalence of chronic diseases and genetic disorders drive the demand for personalized medicines, enhancing the attractiveness of Gene Therapy and Cell Therapy. Additionally, factors such as improved healthcare infrastructure and increasing investments in R&D are fueling growth across all segments, particularly in areas where regulatory environments are supportive of new biologic innovations. Monoclonal Antibodies (Dominant) vs. Cell Therapy (Emerging) Monoclonal Antibodies are characterized by their specificity and versatility, being used extensively in oncology and autoimmune diseases. They command a dominant position in the South Korea biologic therapy market, as healthcare providers increasingly rely on their efficacy and the breadth of their applications. Their regulatory approval processes are well-established, ensuring a consistent supply. On the other hand, Cell Therapy, although currently smaller in market presence, represents a rapidly growing segment. Innovative approaches such as CAR T-cell therapy are revolutionizing treatment options for patients with complex health conditions. As research continues to evolve, Cell Therapy is expected to expand its footprint, catering to more therapeutic areas and demonstrating promising outcomes. ### By Application: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing) The market share distribution in the South Korea biologic therapy market clearly indicates that oncology holds the largest portion, driven by the increasing prevalence of cancer and the growing demand for effective therapies. Autoimmune diseases follow, emerging as a substantial segment, reflecting both rising diagnosis rates and advancements in treatment options that appeal to patients and providers alike. Growth trends in this segment are propelled by ongoing research and development efforts, as well as a heightened focus on personalized medicine. Oncology therapeutics continue to innovate, offering targeted approaches that improve patient outcomes. Conversely, autoimmune diseases are experiencing faster growth, spurred by enhanced awareness and understanding of these conditions, leading to increased investments and breakthroughs in biologic therapies. Oncology (Dominant) vs. Autoimmune Diseases (Emerging) Oncology remains the dominant segment in the South Korea biologic therapy market, largely due to its extensive portfolio of biologic therapies designed specifically for various cancers. This segment benefits from significant investments in research and increasing regulatory approvals for new treatments. On the other hand, autoimmune diseases are recognized as an emerging segment, characterized by an expansion of biologic options targeting conditions such as rheumatoid arthritis and multiple sclerosis. This growth is fueled by advancements in biologic agents that provide better safety profiles and efficacy, thus appealing to a broader patient demographic. As awareness of autoimmune diseases evolves, their respective market positions are likely to strengthen significantly. ### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing) In the South Korea biologic therapy market, the distribution of market share among the different routes of administration highlights a strong preference for intravenous therapies, which currently hold the largest share. The effectiveness and rapid action associated with intravenous delivery systems have contributed significantly to their dominance, appealing to healthcare providers and patients alike. Subcutaneous administration, while significantly smaller in share, is experiencing noteworthy growth as patients and clinicians recognize its convenience and ease of use, positioning it as an emerging contender in the market. Growth trends indicate a shift towards more patient-centric approaches, which is driving the popularity of subcutaneous routes. Factors such as technological advancements in delivery systems and the increased prevalence of chronic diseases necessitate a wide range of administration options. The growing demand for home healthcare services also supports the rapid adoption of subcutaneous administration as it offers a viable alternative for self-administration, easing the burden on healthcare facilities and enhancing the overall patient experience. Administration: Intravenous (Dominant) vs. Subcutaneous (Emerging) The intravenous route of administration remains the dominant modality due to its ability to deliver biologic therapies quickly and effectively, making it a preferred choice in acute care settings. This route is particularly advantageous for patients requiring high-dosage medications or those who cannot tolerate oral medications. Conversely, the subcutaneous method is gaining traction as an emerging option, favored for its user-friendly approach that allows for self-administration, thus enhancing patient compliance. As the healthcare landscape evolves, both routes are expected to coexist, catering to distinct patient needs and preferences while also responding to emerging trends in targeted therapies. ### By End-user: Hospitals (Largest) vs. Home Healthcare (Fastest-Growing) In the South Korea biologic therapy market, hospitals account for the largest share of the end-user segment, demonstrating their critical role in administering biologic therapies. Clinics and home healthcare represent substantial market players but have smaller shares compared to hospitals. The accessibility and infrastructure provided by hospitals make them a preferred choice for patients requiring biologic treatments, thereby solidifying their dominance in this segment. Looking at growth trends, home healthcare is emerging as the fastest-growing segment within the South Korea biologic therapy market. This trend is driven by the increasing preference for personalized treatment at home, advancements in telehealth technologies, and a growing elderly population that requires continuous care. As patients seek comfort and convenience, the home healthcare segment is expected to see significant expansion in the coming years. Hospitals (Dominant) vs. Home Healthcare (Emerging) Hospitals serve as the dominant end-user in the biologic therapy landscape, characterized by comprehensive facilities and specialized staff equipped to handle complex therapies. Their extensive networks allow for substantial patient turnover and access to varied treatment options. Conversely, home healthcare is emerging rapidly as a viable alternative for many patients, driven by technological advancements and a desire for personalized care. This segment offers patients the flexibility of undergoing treatments in familiar surroundings, which is particularly appealing to the aging population. The shift towards home healthcare reflects changing patient preferences and advancements in monitoring technologies, indicating a potential recalibration of market dynamics in favor of this emerging segment. ## Competitive Benchmarking The biologic therapy market in South Korea is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on patient-centric solutions. Major players such as AbbVie (US), Roche (CH), and Johnson & Johnson (US) are at the forefront, each employing distinct strategies to enhance their market presence. AbbVie (US) emphasizes innovation in immunology and oncology, leveraging its robust pipeline to address unmet medical needs. Roche (CH) focuses on personalized medicine, utilizing its expertise in diagnostics to tailor therapies for individual patients. Meanwhile, Johnson & Johnson (US) adopts a diversified approach, integrating biologics into its broader portfolio while investing in digital health solutions to improve patient outcomes. Collectively, these strategies contribute to a competitive environment that prioritizes advanced therapeutic options and patient engagement.Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players holding substantial market shares while also facing competition from emerging biotech firms. This fragmentation allows for a variety of therapeutic options, fostering innovation and driving down prices, albeit with a potential risk of market saturation. In October AbbVie (US) announced a strategic partnership with a local biotech firm to co-develop a novel biologic therapy targeting autoimmune diseases. This collaboration is significant as it not only enhances AbbVie's research capabilities but also strengthens its foothold in the South Korean market, where demand for innovative treatments is on the rise. Such partnerships may facilitate faster development timelines and localized solutions tailored to regional patient needs. In September Roche (CH) launched a new biologic therapy for breast cancer, which was developed in conjunction with advanced diagnostic tools. This move underscores Roche's commitment to personalized medicine, as the therapy is designed to be used in conjunction with specific biomarkers. The strategic importance of this launch lies in its potential to improve treatment outcomes and solidify Roche's leadership in oncology, particularly in a market that increasingly values tailored therapeutic approaches. In August Johnson & Johnson (US) expanded its biologics manufacturing facility in South Korea, a decision that reflects its long-term commitment to the region. This expansion is likely to enhance production capacity and supply chain reliability, positioning the company to better meet local demand. Such investments in infrastructure are crucial as they not only support current operations but also prepare the company for future growth in a competitive landscape. As of November current trends in the biologic therapy market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. Companies that can effectively leverage these trends will likely emerge as leaders in the biologic therapy market, ensuring that they meet the evolving needs of patients and healthcare providers. ## Recent News & Developments Recent developments in the South Korea Biologic Therapy Market have shown significant advancements and strategic movements among key players. In October 2023, LG Chem announced positive results from its clinical trials for a new biologic therapy, potentially enhancing its position in the market. EirGenix has also been expanding its portfolio, with new partnerships aimed at increasing accessibility to its products.  Meanwhile, SK Biopharmaceuticals reported a 15% growth in market valuation due to the successful launch of a novel therapy aimed at neurological disorders. Mergers and acquisitions have marked the recent landscape; for instance, in September 2023, Samsung Biologics completed the acquisition of a smaller biotech firm, enhancing its Production capabilities. In August 2023, Hanmi Pharmaceutical announced a partnership with Genexine for the joint development of a groundbreaking drug targeting autoimmune diseases.  The South Korean Biologic Therapy Market has been bolstered by these strategic moves along with governmental support for biopharmaceutical innovations, which includes incentives for Research and Development initiatives and funding opportunities for start-ups in this sector. These elements collectively indicate a dynamic and rapidly evolving market landscape in South Korea. ## Report Scope | MARKET SIZE 2024 | 7.8(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 8.32(USD Billion) | | MARKET SIZE 2035 | 15.9(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.69% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | AbbVie (US), Amgen (US), Roche (CH), Johnson & Johnson (US), Novartis (CH), Pfizer (US), Bristol-Myers Squibb (US), Sanofi (FR), Gilead Sciences (US) | | Segments Covered | Type, Application, Route of Administration, End-user | | Key Market Opportunities | Emerging gene therapies and personalized medicine drive growth in the biologic therapy market. | | Key Market Dynamics | Rising demand for innovative biologic therapies drives competitive dynamics and regulatory adaptations in South Korea's healthcare sector. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the biologic therapy market in South Korea?** A: The market valuation was $7.8 Billion in 2024. **Q: What is the projected market size for biologic therapy in South Korea by 2035?** A: The market is expected to reach $15.9 Billion by 2035. **Q: What is the expected CAGR for the South Korea biologic therapy market from 2025 to 2035?** A: The expected CAGR during this period is 6.69%. **Q: Which companies are the key players in the South Korea biologic therapy market?** A: Key players include AbbVie, Amgen, Roche, Johnson & Johnson, Novartis, Pfizer, Bristol-Myers Squibb, Sanofi, and Gilead Sciences. **Q: What are the main segments of the biologic therapy market in South Korea?** A: The main segments include Monoclonal Antibodies, Vaccines, Cell Therapy, and Gene Therapy. **Q: How did the market for Monoclonal Antibodies perform in 2024?** A: The market for Monoclonal Antibodies was valued at $2.5 Billion in 2024 and is projected to reach $5.2 Billion by 2035. **Q: What applications dominate the biologic therapy market in South Korea?** A: Oncology and Autoimmune Diseases are the dominant applications, each valued at $2.34 Billion in 2024. **Q: What routes of administration are prevalent in the biologic therapy market?** A: Intravenous and Subcutaneous routes are prevalent, each valued at $2.34 Billion in 2024. **Q: What are the primary end-users of biologic therapy in South Korea?** A: Hospitals are the primary end-users, with a market value of $3.12 Billion in 2024. **Q: How is the market for Cell Therapy expected to grow by 2035?** A: The market for Cell Therapy is projected to grow from $1.2 Billion in 2024 to $2.5 Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-biologic-therapy-market-54506*